reference/17435240

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17435240

Outgoing Links

Predicate	Object
contentType	Journal Article
endingPage	371
issn	1078-8956 1546-170X
issueIdentifier	3
pageRange	368-371
publicationName	Nature Medicine
startingPage	368
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5dcb810f2c1056b8bce88957dd32020c http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_45cf30fa739540ee4c638a3bd3f0c291
bibliographicCitation	Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe JM, Tallman MS, Paganin M, Basso G, Hof J, Kirschner-Schwabe R, Palomero T, Rabadan R, Ferrando A. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013 Mar;19(3):368–71. PMID: 23377281; PMCID: PMC3594483.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ddbe1984a611ae80f00c0b8f0695fd25 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7dc9c4a734b244eabae336957eff16c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26daa9fc14ae928d8a1b58326abacaa3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5a0535640ff6fc85cbfc9e46c6b9224 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1446-4394 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f0444eea5de6f071882e3bcd3ae9c28 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f39cf7452e177a1c782a99814d27faa0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e57a6f3eab948f46754396d658547410 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea92a3b30732c9f4995c5c0fa5f3baff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9b0fa3dedb3280229715c1c3c4b122a7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f61690dee21adad6d7bd578c1309675e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5af1c3954b15d48db216f0f453a38784 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_65dd8604a5c1756a73787f25dfd649f3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9df2093eb6340b74a70f4e3c6589a30e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d3f6119f6f9fa46d5dad57a6dc7aac8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe2ba78a7d07b3d17a8c8630c58dedd5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c13eaacc721bdfe73f865a9131e2b66c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e3be7c00c1496a06f2527a75d223319
date	2013-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC3594483 https://doi.org/10.1038/nm.3078 https://pubmed.ncbi.nlm.nih.gov/23377281
isPartOf	https://portal.issn.org/resource/ISSN/1078-8956 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8791 https://portal.issn.org/resource/ISSN/1546-170X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL
discusses	http://id.nlm.nih.gov/mesh/M0024108 http://id.nlm.nih.gov/mesh/M0495201 http://id.nlm.nih.gov/mesh/M0001642 http://id.nlm.nih.gov/mesh/M0021356 http://id.nlm.nih.gov/mesh/M0023263 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0359430
hasSubjectTerm	http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112 http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11043 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID667490 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.1.3.31 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2723601 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_320e990781343ed266cc0ffc49fbbf5a http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10364 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.1.3.5 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_2fc3804b10af13fc7f6ee3e68d08bae9

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID362631 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID22978

Total number of triples: 61.